68

Shanghai Model Organisms Center Inc

688265 · SHG · Healthcare / Biotechnology

45.60CNY-5.16 (-10.17%)

Price History

Full chart

Market Stats

Previous Close50.76
Open49.98
Day Range45.02 – 50.45
52-Week Range30.26 – 65.05
Volume3.04M
Market Cap5.07B
P/E (TTM)209.61
Forward P/E0.00
EPS0.31
Dividend Yield0.19%
Beta0.36
50-Day Avg43.44
200-Day Avg41.68

About

Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. It uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. The company offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine reporters, inducible cell ablation, and cell-specific reporters. It also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system. Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ruilin Sun
  • Employees959
  • HeadquartersNo. 1, Lane 63, Shanghai, China, 201318, China
  • Websitehttps://www.modelorg.com

Leadership

  • Mr. Ruilin SunDeputy GM & Director · b. 1980
  • Mr. Dongxiao FengDeputy General Manager · b. 1970
  • Mr. Chunming ZhangGM and Chief Financial Officer · b. 1969
  • Mr. Xue YangBoard Secretary · b. 1989

Financials

Income Statement

Currency: CNY2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue45.40M60.52M76.29M121.44M154.80M196.19M275.27M302.97M366.55M381.24M421.26M
Growth (%)-+33.29%+26.07%+59.18%+27.47%+26.74%+40.31%+10.06%+20.99%+4.01%+10.50%
Cost of Revenue16.77M21.27M41.74M69.20M77.66M83.34M109.47M178.47M213.77M208.09M203.40M
Gross Profit28.63M39.25M34.55M52.24M77.14M112.85M165.80M124.50M152.78M173.15M421.26M
Gross Margin63.06%64.86%45.29%43.01%49.83%57.52%60.23%41.09%41.68%45.42%100.00%
Operating Expense17.94M24.59M50.25M36.25M54.37M63.94M97.94M140.87M182.58M170.36M390.57M
Operating Income10.70M14.66M-15.70M15.99M22.77M48.91M67.85M-16.37M-29.80M2.79M30.69M
Operating Margin23.56%24.23%-20.58%13.16%14.71%24.93%24.65%-5.40%-8.13%0.73%7.28%
EBITDA12.96M18.16M-13.09M22.83M31.20M55.55M82.93M8.98M-1.30M42.31M65.48M
EBITDA Margin28.54%30.01%-17.15%18.80%20.15%28.32%30.13%2.96%-0.35%11.10%15.54%
Net Income10.60M14.62M-16.05M15.11M23.25M44.56M60.86M-5.40M-20.58M6.50M32.43M
Net Income Margin23.34%24.16%-21.04%12.44%15.02%22.71%22.11%-1.78%-5.62%1.70%7.70%
R&D8.12M-10.39M17.60M28.69M34.42M47.95M65.76M80.24M74.98M86.69M
R&D as % of Total Revenue17.89%-13.62%14.49%18.53%17.54%17.42%21.70%21.89%19.67%20.58%
Interest Expense--21.08K27.67K34.26K53.34K1.52M5.26M5.16M3.92M2.42M
Interest Expense % of Total Revenue--0.03%0.02%0.02%0.03%0.55%1.74%1.41%1.03%0.57%

Balance Sheet

Currency: CNY2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets111.16M150.72M178.59M191.68M218.70M357.02M1.96B2.05B2.00B1.93B1.98B
Total Liabilities48.98M52.37M81.57M79.56M83.32M102.09M180.40M287.75M260.99M246.36M274.33M
Total Equity60.68M75.30M97.02M112.13M135.38M254.93M1.78B1.77B1.74B1.68B1.71B
Cash82.20M71.57M28.07M52.12M19.49M71.57M1.57B368.03M97.60M200.73M150.39M
Total Debt-----29.13M26.04M120.95M94.76M52.75M-
Net Debt-82.20M-71.57M-28.07M-52.12M-19.49M-42.44M-1.54B-247.09M-2.85M-147.99M-

Cash Flow

Currency: CNY2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow20.43M25.83M8.23M11.75M34.77M59.10M111.46M18.89M20.08M71.56M96.92M
Investing Cash Flow-8.10M-36.71M-51.82M12.30M-67.40M-82.16M-90.27M-951.39M-225.23M109.64M-
Financing Cash Flow38.74M5.23M---75.00M1.47B-265.11M-64.68M-83.10M-
Capital Expenditure3.31M27.08M44.80M2.49M2.16M102.97M52.36M270.26M124.30M25.24M45.61M
Free Cash Flow17.12M-1.24M-36.57M9.25M32.61M-43.86M59.10M-251.37M-104.22M46.33M51.31M
Dividends Paid1.26M------20.04M404.67K10.00M-
FCF to OCF83.82%-4.82%-444.14%78.77%93.77%-74.22%53.02%-1330.45%-518.96%64.74%52.94%
Dividend Paid to FCF7.37%-------7.97%-0.39%21.59%-

Earnings

Report DateApr 27, 2022Aug 29, 2022Oct 28, 2022Apr 27, 2023
EPS Estimate----
EPS Actual0.28-0.120.04-0.17
Surprise----
TimingPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap5.07B
Enterprise Value3.32B
Trailing P/E209.61
Forward P/E0.00
Price / Sales11.07
Price / Book2.42
EPS0.31
Book Value22.23
Revenue (TTM)457.70M
Gross Profit (TTM)238.10M
EBITDA24.72M
Profit Margin4.88%
Operating Margin-1.71%
Return on Equity1.31%
Return on Assets-0.23%
Shares Outstanding77.96M
Shares Float30.47M
Beta0.36
Dividend Yield0.19%
Dividend Rate0.13
Payout Ratio0.00%

Dividends

20261×
0.13Jul 13, 2026
20241×
0.13Jul 19, 2024
20221×
0.26Jul 13, 2022